Literature DB >> 10998662

New therapies for functional bowel diseases.

B Coulie1, M Camilleri.   

Abstract

During recent years, a greater understanding of the pathophysiology of functional bowel disease, and a surge of interest in this challenge among pharmacologists, basic scientists, and clinical investigators, have led to novel insights and promising therapies. The evidence to support current therapies in nonculcer dyspepsia and irritable bowel syndrome (IBS) is reviewed, and some of the novel therapeutic approaches on the threshold of clinical application are described.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998662     DOI: 10.1007/s11894-000-0034-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  67 in total

Review 1.  Definition and investigation of dyspepsia. Consensus of an international ad hoc working party.

Authors:  L Barbara; M Camilleri; R Corinaldesi; G P Crean; R C Heading; A G Johnson; J R Malagelada; V Stanghellini; M Wienbeck
Journal:  Dig Dis Sci       Date:  1989-08       Impact factor: 3.199

Review 2.  Management of nonulcer dyspepsia.

Authors:  R S Fisher; H P Parkman
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

3.  American Gastroenterological Association medical position statement: evaluation of dyspepsia.

Authors: 
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

4.  Psychological significance of the irritable colon syndrome.

Authors:  I G Hislop
Journal:  Gut       Date:  1971-06       Impact factor: 23.059

5.  Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia.

Authors:  N J Talley; N Vakil; E D Ballard; M B Fennerty
Journal:  N Engl J Med       Date:  1999-10-07       Impact factor: 91.245

6.  Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans.

Authors:  A B Gorelick; S S Koshy; F G Hooper; T C Bennett; W D Chey; W L Hasler
Journal:  Am J Physiol       Date:  1998-09

7.  Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency.

Authors:  M Read; N W Read; D C Barber; H L Duthie
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

8.  Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.

Authors:  M Dapoigny; J L Abitbol; B Fraitag
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

9.  The effect of loperamide on anorectal function in normal healthy men.

Authors:  F Musial; P Enck; K T Kalveram; J F Erckenbrecht
Journal:  J Clin Gastroenterol       Date:  1992-12       Impact factor: 3.062

10.  Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride.

Authors:  R Jian; F Ducrot; A Ruskone; S Chaussade; J C Rambaud; R Modigliani; J D Rain; J J Bernier
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.